|
CNBC'S MOST SHARED
- 'We're in the Middle of a Crash': Black Swan
- A Goldman Trading Scandal?
- The Rising Mountain of Debt May Be the Next Crisis
- Cuddle Parties Heat Up
- Latvian Banker Taking Souls as Collateral
- Alaska Governor Sarah Palin Will Resign
- Malaysia PM Speaks to CNBC
- SEC May Reinstate Rules for Short-Selling Stocks
- Your First Move For Monday July 6th
- BOJ Shirakawa: Japan Corporate Finance Still Tight
- China Reassures on Dollar Debate Before G8
- Obama Heads to Moscow for 'Reset' Summit
- Alcoa to Post Loss — What Does This Mean?
- UK Spy Chief's Wife Posts Life on Facebook
- A Goldman Trading Scandal?
- Partner Re to Buy Paris Re in $2 Billion Deal
- Obama Plan Would Trim Back Financial Powerhouses
- Biden: 'We Misread How Bad The Economy Was'
- Market 360: The Week's Best & Worst
- Fireworks At Pharma's Market
- Value of Warren Buffett's Annual Gift to Gates Foundation Falls Along With Berkshire's Stock
- Michael Jackson: The Music And The Money
- Five Stock Picks for This Market
- Realities of the New Obama Refis
- Weak Dollar Means Gold at $1,040: Strategist
- Court Ruling Could Mean Trouble for TiVo
- Lance, Please Back Out Of Tour
Pfizer, which is struggling to remain competitive amid generic competition for many of its products, Wednesday said it hopes to expand its sales in Asia and other emerging markets.
The world's largest drugmaker also said in a release, ahead of a meeting with industry analysts, that it will establish a new business unit focusing on cancer drugs and aims to significantly boost the number of its drugs in late-stage trials by late next year.
Pfizer [PFE
Loading...
()
] in the past year has cut more than 10,000 jobs and is paring other costs to keep earnings growing amid generic competition for antidepressant Zoloft, blood pressure treatment Norvasc and its Zyrtec antihistamine. It is also bracing for the U.S. patent expiration, possibly by 2010, for its Lipitor cholesterol fighter.
Pfizer shares were up nearly 1 percent in premarket trading.









